HER2、HER3蛋白表达与Gefitinib疗效的关系

The correlation between the expressions of HER2 and HER3 and the efficacy of gefitinib treatment

目的:探讨非小细胞肺癌组织中HER2、HER3的表达与Gefitinib疗效的关系。方法:采用免疫组织化学SP法,检测Gefitinib治疗前非小细胞肺癌组织中HER2和HER3的表达情况,并分析其与Gefitinib疗效的关系。结果:61例非小细胞肺癌组织中,HER2、HER3蛋白高表达率分别为50.8%和18.0%。HER2,HER2、HER3蛋白联合表达与Gefitinib的疗效没有明显关系(P>0.05),但高表达组Gefitinib的有效率几乎均是相应低表达组的2～3倍,中位生存期均长于相应低表达组。结论:HER2,HER2、HER3蛋白联合表达水平可能与Gefitinib的疗效有关,需要扩大样本进一步研究证实。

Objective To investigate the correlation between the expressions of HER2, HER3 and the efficacy of gefitinib treatment. Method Sixty-one patients with non-small-cell lung carcinoma were enrolled in the study. Before the patients took in gefitinib, tumor tissue specimens were collected and used to determine the expressions of HER2 and HER3 by using immunohistochemistry （SP methods）. Results The over-expressing rates of HER2 and HER3 were 50.8% and 18.0%, respectively. No correlation between the expressions of HER2 and HER3 and the efficacy of gefitinib tratment （P 〉 0.05） was found, but the response rate was two to three times in the over-expressing HER2, HER2＋3 groups than that of less-expressing groups, and the median survival time was also longer than that of the corresponding groups. Conclusion The expression rates of HER2 and HER2＋3 seem to be pertinent to the efficacy of gefitinib treatment, but an even big sample will be needed to confirm the hypothesis.